TY - JOUR
T1 - Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction
T2 - a meta-analysis
AU - Yong, Jie Ning
AU - Ng, Cheng Han
AU - Lee, Chloe Wen Min
AU - Chan, Yu Yi
AU - Tang, Ansel Shao Pin
AU - Teng, Margaret
AU - Tan, Darren Jun Hao
AU - Lim, Wen Hui
AU - Quek, Jingxuan
AU - Xiao, Jieling
AU - Chin, Yip Han
AU - Foo, Roger
AU - Chan, Mark
AU - Lin, Weiqin
AU - Noureddin, Mazen
AU - Siddiqui, Mohammad Shadab
AU - Muthiah, Mark D.
AU - Sanyal, Arun
AU - Chew, Nicholas W.S.
N1 - Funding Information:
Arun J. Sanyal: Dr Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Enyo, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer-Ingelheim, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Norvatis. He receives royalties from Elsevier and UptoDate. Mazen Noureddin: has been on the advisory board for 89BIO, Gilead, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Terns, Siemens and Roche diagnostic; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking and Zydus; MN is a minor shareholder or has stocks in Anaetos, Rivus Pharma and Viking. All other authors have no conflicts of interests.
Publisher Copyright:
© 2022, Asian Pacific Association for the Study of the Liver.
PY - 2022/4
Y1 - 2022/4
N2 - Objective: Several studies have documented a relationship between non-alcoholic fatty liver disease (NAFLD) and structural heart disease, particularly diastolic function. This meta-analysis will be the first to examine the echocardiographic-derived cardiac function and structural characteristics in NAFLD patients, and its association with liver disease severity and metabolic profile. Methods: Medline and Embase were searched and pairwise meta-analysis was conducted in DerSimonian and Laird to obtain the odds ratio (OR) and mean difference (MD) for dichotomous and continuous variables, respectively, to compare the effects of NAFLD on the echocardiography parameters. Results: Forty-one articles involving 33,891 patients underwent echocardiography. NAFLD patients had worse systolic indices with lower ejection fraction (EF, MD: − 0.693; 95% CI: − 1.112 to − 0.274; p = 0.001), and worse diastolic indices with higher E/e’ (MD: 1.575; 95% CI: 0.924 to 2.227; p < 0.001) compared to non-NAFLD patients. NAFLD patients displayed increased left ventricular mass (LVM, MD: 34.484; 95% CI: 26.236 to 42.732; p < 0.001) and epicardial adipose thickness (EAT, MD: 0.1343; 95% CI: 0.055 to 0.214; p = 0.001). An increased severity of NAFLD was associated with worse diastolic indices (decreased E/A ratio, p = 0.007), but not with systolic indices. Conclusions: NAFLD is associated with impaired systolic and diastolic function with changes in cardiac structure. Concomitant metabolic risk factors and liver disease severity are independently associated with worsening systolic and diastolic function. Graphical abstract: [Figure not available: see fulltext.]
AB - Objective: Several studies have documented a relationship between non-alcoholic fatty liver disease (NAFLD) and structural heart disease, particularly diastolic function. This meta-analysis will be the first to examine the echocardiographic-derived cardiac function and structural characteristics in NAFLD patients, and its association with liver disease severity and metabolic profile. Methods: Medline and Embase were searched and pairwise meta-analysis was conducted in DerSimonian and Laird to obtain the odds ratio (OR) and mean difference (MD) for dichotomous and continuous variables, respectively, to compare the effects of NAFLD on the echocardiography parameters. Results: Forty-one articles involving 33,891 patients underwent echocardiography. NAFLD patients had worse systolic indices with lower ejection fraction (EF, MD: − 0.693; 95% CI: − 1.112 to − 0.274; p = 0.001), and worse diastolic indices with higher E/e’ (MD: 1.575; 95% CI: 0.924 to 2.227; p < 0.001) compared to non-NAFLD patients. NAFLD patients displayed increased left ventricular mass (LVM, MD: 34.484; 95% CI: 26.236 to 42.732; p < 0.001) and epicardial adipose thickness (EAT, MD: 0.1343; 95% CI: 0.055 to 0.214; p = 0.001). An increased severity of NAFLD was associated with worse diastolic indices (decreased E/A ratio, p = 0.007), but not with systolic indices. Conclusions: NAFLD is associated with impaired systolic and diastolic function with changes in cardiac structure. Concomitant metabolic risk factors and liver disease severity are independently associated with worsening systolic and diastolic function. Graphical abstract: [Figure not available: see fulltext.]
KW - Diastolic dysfunction
KW - Diastolic indices
KW - Echocardiography
KW - Epicardial adipose thickness
KW - Liver disease severity
KW - Metabolic profile
KW - Non-alcoholic fatty liver disease
KW - Structural heart disease
KW - Systolic dysfunction
KW - Systolic indices
UR - http://www.scopus.com/inward/record.url?scp=85126899488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126899488&partnerID=8YFLogxK
U2 - 10.1007/s12072-022-10319-6
DO - 10.1007/s12072-022-10319-6
M3 - Review article
C2 - 35320497
AN - SCOPUS:85126899488
SN - 1936-0533
VL - 16
SP - 269
EP - 281
JO - Hepatology International
JF - Hepatology International
IS - 2
ER -